Long‐term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE‐1)*-Reference-Cited by-同舟云学术

Long‐term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE‐1)*

Published:2020-07-05 Issue:6 Volume:183 Page:1037-1048
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br. J. Dermatol.

Author:

Papp K.¹^ORCID,Menter A.²,Leonardi C.³,Soung J.⁴,Weiss S.⁵,Pillai R.⁶,Jacobson A.⁷

Affiliation:

1. Probity Medical Research and K Papp Clinical Research Waterloo ON Canada

2. Baylor Scott & White Dallas TX USA

3. Central Dermatology St. Louis MO USA

4. Southern California Dermatology Santa Ana CA USA

5. Direct Dermatology Palo Alto CA USA

6. Bausch Health US, LLC Petaluma CA USA

7. Ortho Dermatologics (a division of Bausch Health US, LLC) Bridgewater NJ USA

Funder

Ortho Dermatologics

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.19132

Reference28 articles.

1. Biologic fatigue in psoriasis

2. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris

3. Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

4. Adherence to medication in patients with psoriasis: a systematic literature review

5. Identifying individual psychosocial and adherence support needs in patients with psoriasis: a multinational two‐stage qualitative and quantitative study

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Data on Brodalumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: An Observational Study from the Czech Republic BIOREP Registry;Advances in Therapy;2024-08-29

2. The Impact of Psoriasis Treatments on the Risk of Skin Cancer: A Narrative Review;Advances in Therapy;2024-08-28

3. Sequential interleukin-17 inhibitors for moderate-to-severe plaque psoriasis who have an IL-17 inhibitors failure in a resource limited country: An economic evaluation;PLOS ONE;2024-08-09

4. Research trends and hotspots in biologics for plaque psoriasis: A bibliometric study from 2004 to 2023;Heliyon;2024-08

5. Biologics for Psoriasis;Dermatologic Clinics;2024-07